In 2006, the Food and Drug Administration launched a program to require drug makers to win approval of medicines that — believe it or not — were being sold without the agency’s imprimatur or remove them from the market. At the time, hundreds of treatments were readily available because some companies failed to comply with a 1962 law mandating companies prove drugs were effective.
Unfortunately, the FDA effort has had some unforeseen consequences.
Is UDI why tetracycline went on shortage and there were significant price increases? Plaquenil?
Comments are closed.